Pilulka Lékárny has completed an SPO on the START Market of the Prague Stock Exchange
Pilulka Lékárny, a.s. has completed an SPO on the START Market of the Prague Stock Exchange consisting of a capital increase through subscription of new shares. The funds will be used to further develop the company, particularly to strengthen its working capital, to bolster its activities in international markets and to further develop its own e-health solutions.
Since its foundation in 2013, Pilulka has emerged as a leading online pharmacy in central Europe and the operator of a network of franchise and select brick-and-mortar pharmacies in the Czech Republic. Pilulka operates in the Czech Republic, Slovakia and Romania, and entered the Austrian and Hungarian markets in 2022. Pilulka is the number one pharmacy e-shop in-home delivery in the Czech Republic and Slovakia, and among the top three retail pharmacy chains in the Czech Republic.
Oaklins’ team in the Czech Republic acted as an SPO manager in this transaction. The team succeeded in attracting orders from retail investors and high-net-worth individuals.
Prata med transaktionsteamet
Relaterade affärer
OBI Group has acquired the OBI and individual DIG stores from Migros
As part of a strategic review, Migros has decided to divest its DIY business, which included several “Do It + Garden” and “OBI” locations. Migros had operated the Swiss OBI stores as a franchisee. In OBI Group Holding, Migros has found the ideal partner to ensure continuity for both its customers and employees.
Lär dig merAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Lär dig merXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Lär dig mer